Short Interest in Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY) Decreases By 50.9%

Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY) was the target of a large drop in short interest during the month of February. As of February 28th, there was short interest totalling 5,400 shares, a drop of 50.9% from the February 13th total of 11,000 shares. Based on an average daily volume of 9,900 shares, the short-interest ratio is currently 0.5 days.

Santen Pharmaceutical Stock Up 3.1 %

OTCMKTS:SNPHY opened at $9.83 on Friday. Santen Pharmaceutical has a 1 year low of $8.65 and a 1 year high of $13.00. The business has a 50 day simple moving average of $9.66 and a 200-day simple moving average of $10.87.

Santen Pharmaceutical Company Profile

Santen Pharmaceutical Co, Ltd. engages in the research and development, manufacture, and marketing of pharmaceuticals and medical devices in Japan and internationally. Its product portfolio includes tafluprost/timolol maleate, a prostaglandin F2a derivative and a beta-adrenergic receptor blocker; and netarsudil mesilate and latanoprost, a prostaglandin F2a derivative which is marketing approval phase for the treatment of glaucoma and ocular hypertension.